Mast Therapeutics Inc (MSTX) Downgraded by Zacks Investment Research to “Hold”
According to Zacks, “Mast Therapeutics Inc. is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments. The company’s lead product candidate is MST-188 for treating serious or life-threatening diseases. Mast Therapeutics, Inc., formerly known as ADVENTRX Pharmaceuticals, Inc., is based in San Diego, California. “
Several other research firms also recently commented on MSTX. Maxim Group set a $5.00 price objective on Mast Therapeutics and gave the stock a buy rating in a research note on Thursday, September 8th. Laidlaw downgraded Mast Therapeutics from a buy rating to a neutral rating in a research note on Wednesday, September 21st. Roth Capital reaffirmed a buy rating and issued a $2.00 price objective on shares of Mast Therapeutics in a research note on Friday, July 15th. Canaccord Genuity reissued a buy rating and set a $3.00 target price on shares of Mast Therapeutics in a research note on Thursday, July 28th. Finally, Cowen and Company downgraded Mast Therapeutics from an outperform rating to a market perform rating in a research note on Friday, September 23rd. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of Hold and a consensus target price of $2.56.
Mast Therapeutics (NASDAQ:MSTX) opened at 0.091 on Wednesday. The company’s market cap is $19.28 million. The firm’s 50-day moving average is $0.34 and its 200 day moving average is $0.36. Mast Therapeutics has a 12-month low of $0.09 and a 12-month high of $0.71.
Mast Therapeutics (NASDAQ:MSTX) last announced its earnings results on Tuesday, August 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, equities analysts expect that Mast Therapeutics will post ($0.19) earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Mast Therapeutics stock. Vanguard Group Inc. boosted its position in shares of Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned about 3.11% of Mast Therapeutics worth $2,818,000 at the end of the most recent quarter.
About Mast Therapeutics
Mast Therapeutics, Inc is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options.
Receive News & Stock Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related stocks with our FREE daily email newsletter.